Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma

Next Previous
X
Search
Trial Profile

A Randomized, Open-Label, Multi-Center, Phase 2 Study of Zevalin ([90Y]- Ibritumomab Tiuxetan) Versus Zevalin and Motexafin Gadolinium in Patients With Rituximab- Refractory Low-grade or Follicular B-cell Non-Hodgkin's Lymphoma

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 08 Oct 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Motexafin gadolinium (Primary) ; Ibritumomab tiuxetan; Rituximab
  • Indications B-cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Sponsors Spectrum Pharmaceuticals

    • Most Recent Events

    • 02 Jun 2015 Planned End Date changed from 1 Jul 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
    • 26 Mar 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
    • 16 Apr 2012 Status changed from active, no longer recruiting to recruiting as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top